AGEN

Agenus Inc

Add to Watchlist

Advanced Chart

4.270

-0.53(-11.042%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.590

Open

4.420

VWAP

4.29

Vol

1.01M

Mkt Cap

117.07M

Low

4.060

Amount

4.32M

EV/EBITDA(TTM)

Total Shares

21.00M

160.47M

EV/OCF(TTM)

P/S(TTM)

1.02

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

0.00

-100%

24.77M

-7.69%

24.98M

-0.53%

Estimates Revision

The market is revising Upward the revenue expectations for Agenus Inc. (AGEN) for FY2025, with the revenue forecasts being adjusted by 50.67% over the past three months. During the same period, the stock price has changed by 22.00%.

Revenue Estimates for FY2025

Revise Upward

+50.67%

In Past 3 Month

Stock Price

Go Up

+22.00%

In Past 3 Month

5 Analyst Rating

160.66% Upside

Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 11.13 USD with a low forecast of 5.50 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

160.66% Upside

Current: 4.270

Low

5.50

Averages

11.13

High

25.00

160.66% Upside

Current: 4.270

Low

5.50

Averages

11.13

High

25.00

H.C. Wainwright

Neutral -> Buy

upgrade

$25

2025-06-04

Reason

H.C. Wainwright

Price Target

$25

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.

Baird

Neutral

maintain

$4 -> $6

2025-06-04

Reason

Baird

Price Target

$4 -> $6

2025-06-04

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.

Baird

Neutral

maintain

$3 -> $4

2025-05-13

Reason

Baird

Price Target

$3 -> $4

2025-05-13

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

n/a

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

n/a

2025-03-18

Reiterates

Hold

Reason

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

n/a

2025-03-12

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

n/a

2025-03-12

Reiterates

Hold

Reason

Baird

Colleen Kusy

Hold

Maintains

$6 → $3

2025-03-12

Reason

Baird

Colleen Kusy

Price Target

$6 → $3

2025-03-12

Maintains

Hold

Reason

Baird lowered the firm's price target on Agenus to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and looks to focus on operational efficiency.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Agenus Inc (AGEN.O) is 4.81, compared to its 5-year average forward P/E of -4.71. For a more detailed relative valuation and DCF analysis to assess Agenus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.71

Current PE

4.81

Overvalued PE

19.26

Undervalued PE

-28.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.67

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.70

Undervalued EV/EBITDA

-2.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.63

Current PS

0.83

Overvalued PS

10.97

Undervalued PS

0.30